How should costs and cost-effectiveness be considered in prenatal genetic testing?
Tài liệu tham khảo
Buelen, 2014, The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effective analysis, Eur J Obstet Gynecol Reprod Bio, 182, 53, 10.1016/j.ejogrb.2014.08.028
Fairbrother, 2016, Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effective analysis, J Matern Fetal Neonat Med, 29, 1160, 10.3109/14767058.2015.1038703
Skirton, 2013, Factors affecting the clinical use of non-invasive prenatal testing: a mixed-methods systematic review, Prenat Diagn, 33, 532, 10.1002/pd.4094
Odibo, 2005, A cost-effectiveness analysis of prenatal screening strategies for down syndrome, Obstet Gynecol, 106, 562, 10.1097/01.AOG.0000174581.24338.6f
Musci, 2005, Cost-effectiveness analysis of prenatal population-based fragile X carrier screening, Am J Obstet Gynecol, 192, 1905, 10.1016/j.ajog.2005.02.052
Norman, 2012, Cost-effectiveness of carrier screening for cystic fibrosis in Australia, J Cystic Fibrosis, 11, 281, 10.1016/j.jcf.2012.02.007
Ohno, 2013, The role of non-invasive prenatal testing as a diagnostic versus a screening tool – a cost-effective analysis, Prenat Diagn, 33, 630, 10.1002/pd.4156
Gawande
Downe, 2016, What matters to women: a systematic scoping review to identify the processes and outcomes of antenatal care provision that are important to healthy pregnant women, BJOG, 123, 529, 10.1111/1471-0528.13819
Pitchforth, 2008, Models of intrapartum care and women's trade-offs in remote and rural Scotland: a mixed-methods study, BJOG, 115, 560, 10.1111/j.1471-0528.2007.01516.x
Sparks, 2015, How do maternal views of delivery outcomes vary by demographics and preferred mode of delivery?, Am J Perinatol, 32, 741, 10.1055/s-0034-1395480
Sjetne, 2015, A questionnaire to measure women's experiences with pregnancy, birth and postnatal care: Instrument development and assessment following a national survey in Norway, BMC Preg Childbirth, 15, 182, 10.1186/s12884-015-0611-3
Hundley, 2001, Assessing women's preferences for intrapartum care, Birth, 28, 254, 10.1046/j.1523-536X.2001.00254.x
Kuppermann, 2016, Preferences regarding contemporary prenatal genetic tests among women desiring testing: Implications for optimal testing strategies, Prenat Diagn, 36, 469, 10.1002/pd.4808
McAllister, 2015, Patient reported outcomes and patient empowerment in clinical genetics services, Clin Genet, 88, 114, 10.1111/cge.12520
Halvorson, 2017, Transitioning from volume to value: One academic medical center's approach to improving population health, Acad Medicine, 92, 666, 10.1097/ACM.0000000000001536
Health Care Payment Learning & Action Network. (2016, August 1). Retrieved from: https://hcp-lan.org/groups/cep/clinical-episode-payment/. Accessed May 23, 2017.
Wilson, 2016, Joint SOGC-CCMG Opinion for reproductive genetic carrier screening: An update for all Canadian providers of maternity and reproductive healthcare in the era of direct-to-consumer testing, J Obstet Gynaecol Can, 38, 742, 10.1016/j.jogc.2016.06.008
CROWN: Core outcomes in women's and newborn health. Retrieved from: http://www.crown-initiative.org/14-2/aims-and-scope/. Accessed May 25, 2017.
Society for Maternal-Fetal Medicine. Choosing wisely: five things physicians and patients should question. (2016, February). Retrieved from: https://s3.amazonaws.com/cdn.smfm.org/publications/221/download-96dc1b3ad387b03019245ebb67d16c2b.pdf.
Athem: Chromosomal microarray analysis (CMA) for developmental delay, autism spectrum disorder, intellectual disability (intellectual developmental disorder) and congenital anomalies. (2016, October 4). Retrieved from: https://www.anthem.com/medicalpolicies/policies/mp_pw_c139365.htm.
United Healthcare Community Plan: Chromosomal microarray testing. (2017, February 1). Retrieved from: https://www.unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/Policies%20and%20Protocols/Medical%20Policies/C&S/chromosome_microarray_testing_CS.pdf.
Cigna Medical Coverage Policy: Genetic testing for reproductive carrier screening and prenatal diagnosis. (2017, August 15). Retrieved from: https://cignaforhcp.cigna.com/public/content/pdf/coveragePolicies/medical/mm_0514_coveragepositioncriteria_genetic_testing_repro_carrier_prenatal.pdf.
State medicaid coverage of perinatal services. (2009, November). Retrieved from: https://kaiserfamilyfoundation.files.wordpress.com/2013/01/8014.pdf.
2016, Practice bulletin no. 162: prenatal diagnostic testing for genetic disorders, Obstet Gynecol, 127, e108, 10.1097/AOG.0000000000001405
Bryant, 2015, Variation in women's understanding of prenatal testing, Obstet, 125, 1306, 10.1097/AOG.0000000000000843
Kuppermann, 2006, Beyond race or ethnicity and socioeconomic status, Obstet Gynecol, 107, 1087, 10.1097/01.AOG.0000214953.90248.db
Naqvi, 2016, Chromosomal microarray use among women undergoing invasive prenatal diagnosis, Prenat Diagn, 36, 656, 10.1002/pd.4835
Khoshnood, 2004, Socioeconomic barriers to informed decision making regarding maternal serum screening for Down syndrome: Results of the French national perinatal survey of 1998, Am J Pub Health, 94, 484, 10.2105/AJPH.94.3.484
Wong, 2014, Socioeconomic disparities in diagnostic testing after positive aneuploidy screening, Am J Perinatol, 32, 205, 10.1055/s-0034-1381320
Hart, 2005, Rural definitions for health policy and research, Am J Public Health, 95, 1149, 10.2105/AJPH.2004.042432
2014, ACOG committee opinion no. 586: health disparities in rural women, Obstet Gynecol, 123, 384
Jones, 2017, Abortion incidence and service availability in the United States, 2014, Perspect Sex Reprod Health, 49, 17, 10.1363/psrh.12015
Bianchi, 2015, From prenatal genomic diagnosis to fetal personalized medicine: progresses and challenges, Nat Med, 18, 1041, 10.1038/nm.2829
O'Brien, 2014, Maternal plasma DNA testing: experience of women counseled at a prenatal diagnosis center, Genet Test Molec Biomark, 18, 665, 10.1089/gtmb.2014.0125
Allyse, 2015, Non-invasive prenatal testing: A review of international implementation and challenges, Int J Women's Health, 7, 113, 10.2147/IJWH.S67124
Minear, 2015, Noninvasive prenatal genetic testing: current and emerging ethical, legal, and social issues, Ann Rev Genomics Hum Genet, 16, 369, 10.1146/annurev-genom-090314-050000
U.S. Food and Drug Administration: Nucleic acid based tests. Retrieved from: https://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm330711.htm. Accessed May 25, 2017.
Evans, 2015, The FDA and genomic tests – getting regulation right, NEJM, 372, 2258, 10.1056/NEJMsr1501194
The public health evidence for FDA oversight of laboratory developed tests: 20 case studies. (2015, November 16). Retrieved from: https://www.fda.gov/aboutfda/reportsmanualsforms/reports/ucm472773.htm. Accessed May 25, 2017.
The CLIA Framework. Retrieved from: https://www.genome.gov/pages/policyethics/genetictesting/the_clia_framework.pdf. Accessed May 25, 2017.
National Society of Genetic Counselors: Direct access to genetic testing. (2015, June 9). Retrieved from: http://www.nsgc.org/p/bl/et/blogaid=370. Accessed May 25, 2017.